Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries has reported that its US affiliate, Taro Pharmaceuticals USA, has received approval from the FDA for its new drug application for Flo-Pred equivalent to 5mg/5mL and 15mg/5mL prednisolone in Taro's patent-protected NonSpil liquid drug delivery system.
Subscribe to our email newsletter
The company said that the Flo-Pred (prednisolone acetate oral suspension) brand, for which there are no generic equivalents, will be sold by prescription as an anti-inflammatory agent for the treatment of asthma, certain allergic and dermatologic conditions, as well as a variety of other indications.
The company plans to launch the product later in 2008 and market it through its TaroPharma Division of Taro USA.